84 press releases in English indexed under medical devices.
The global Magnetic Particle Imaging market is expected to experience significant expansion through 2034, reflecting its growing potential in medical imaging, diagnostic research, and emerging healthcare technologies. The Magnetic Particle Imaging market size is projected to increase from US$ 117.60 ... Read more
Whenever fever strikes nine-year-old Joshua Ekimwere in his rural Ogaramio village, getting help has not always been easy. For his grandmother, Akurut Dinah Loy, a suspected malaria infection often meant difficult choices. Either finding money for transport and medicine, missing a day's work, or waiting anxiously while his condition worsens. For years, this was the reality for many families in rural Uganda. Community-based malaria services helped protect children under five, but older children and adults often had to travel long distances to a health facility just to find out whether they had malaria and begin treatment. Today, that is changing. Through a Ministry of Health-led initiative, Village Health Teams (VHTs) and Community Health Extension Workers (CHEWs) are being trained and equipped to test people of all ages using rapid diagnostic tests and provide free lifesaving treatment within their communities. For Akurut Dinah Loy and her family, the difference has been significant. “It is frightening to watch a child become sick and not know how quickly you can get help. Having services nearby has changed a lot for our family,” she said. “Now, when Joshua gets sick, I no longer think first about the journey to the health facility. I think about getting him help quickly.” Improving access to timely care Uganda has made remarkable progress in the fight against malaria. Since 2000, malaria-related deaths have fallen by more than 50%, reflecting sustained investments in prevention, diagnosis and treatment. Yet malaria remains one of the country's most significant public health challenges. In 2025, an estimated 13.2 million malaria cases were reported, meaning roughly one in every 20 malaria cases worldwide occurred in Uganda. WHO estimates that between 16,000 and 20,000 people died from malaria during the same year. Many challenges affecting the fight against malaria include people reaching health services too late, waiting more than 24 hours after symptoms begin before seeking care and relying on poor-quality medicines or fail to complete treatment. These delays increase the risk of severe illness and place additional pressure on families and the health system. The expansion of community-based malaria services is helping address these challenges by making diagnosis and treatment available where people live, particularly in areas where access to health facilities remains difficult. For Dr Cathrine Maiteki Sebuguzi, Deputy Programme Manager at the National Malaria Elimination Department, timely access to care is critical to sustaining Uganda's progress. “Reaching communities where transmission occurs is the foundation of our efforts towards malaria elimination. Through this initiative, we are ensuring timely diagnosis, prompt treatment and protection of those most at risk,” said Dr Cathrine. Strengthening primary health care and advancing equity The initiative does more than improve access to malaria services. It strengthens primary health care by expanding the role of community health workers and ensuring that essential services reach people who might otherwise be left behind. Today, approximately 85,000 VHT members provide community-based health services across Uganda. Extending malaria diagnosis and treatment to all age groups helps address a larger reservoir of infection while improving equity in access to essential health services. The expansion of VHTs and CHEWs is part of Uganda's 24-2 Hours Initiative, which aims to ensure malaria diagnosis and treatment within 24 hours of symptom onset and lifesaving pre-referral treatment for severe malaria within two hours. By reaching rural, peri-urban and underserved communities, the initiative is helping accelerate progress towards Universal Health Coverage. “When health services are available closer to home, people can get help earlier. That is especially important for malaria, where timely diagnosis and treatment can save lives,” said Dr Christine Chiedza Musanhu, Team Lead for Disease Prevention and Control, WHO Uganda. “Community-based care also helps us reach people who might otherwise be left behind.” The programme is supported through a broad partnership involving the Global Fund, the United States Government and UNICEF. For Akurut Dinah Loy, the success of this initiative means knowing that when Joshua develops a fever, help is no longer a distant journey away. “As a grandmother, nothing is more important than seeing my grandchildren healthy. Knowing they can be tested and treated quickly gives our family comfort and hope,” added Loy. For families across Uganda, timely access to malaria services means fewer delays, less uncertainty and a better chance of receiving treatment when it matters most. And for Uganda, it is another step towards a future where no family's health is determined by how far they live from care. Distributed by APO Group on behalf of WHO Regional Office for Africa.
STEMart launches a range of Gel Imaging System solutions to support molecular biology research, electrophoresis analysis, and laboratory documentation. NEW YORK, NY, UNITED STATES, October 23, 2026 / EINPresswire.com / -- STEMart , a US-based provider of comprehensive services and technical solutions for all phases of medical device development, has launched a range of Gel Imaging System solutions to support molecula
JOHANNESBURG Friday Oct 23, 2026 @ 2:00 AM UTC — Life Masters, the Johannesburg-based high performance team development company led by founder Tony Dovale, has launched the Revolutionary Workplace® Leadership Alignment Accelerator, a programme and diagnostic process for repairing and aligning fractured executive, exco, management and board teams. Programmes are offered in Gauteng, South Africa, with bookings opening in January 2027. The launch addresses a common yet often unmeasured issue in South African organizations: misaligned leadership leading to strain throughout the company. Decision-making slows, strategies falter in execution, and board-level tension affects company culture and performance. "When an executive team is pulling in different directions, everything below it feels the strain, " said Tony Dovale, CEO, Life Masters. "We built the Leadership Alignment Accelerator so management, executive and board teams can see clearly where they are out of step and work through it together. Starting with talks and board interview meetings lets us meet each team where it actually is." What the Accelerator is Life Masters' Accelerator integrates leadership team diagnostics with guided sessions. These diagnostics reveal fractures within the team and highlight misalignments among members concerning priorities, decision rights, trust, and communication. The facilitated sessions then work through those gaps with the whole team together, rather than with leaders one by one. The result is a shared, tested understanding of what the team is there to achieve and how it will make decisions, resolve conflict and hold each other to account. Who it is for The Accelerator is designed for management teams, executive teams and boards, particularly where: Decisions are slow or repeatedly reopened Strategy execution has stalled There is tension or distrust at board or exco level Leaders are pulling in different directions or working to competing priorities A new CEO, merger or restructure has left the leadership team unaligned How engagements work Each engagement is tailored to meet the specific outcomes desired by the client. Some run as a two-day leadership retreat. Others run as multi-month alignment and optimisation projects. The format depends on the organisation’s structure, locations, number of participants and the depth of process needed to resolve the fractureLeadership teams face mounting pressure to adapt swiftly amidst technological shifts, economic unpredictability, and evolving stakeholder demands. Without internal alignment, leading change becomes a formidable challenge. Life Masters' solutions are designed to address these challenges effectively.ns. A team that cannot align internally cannot lead changLeadership teams often fail not due to lack of talent but because they drift apart without measurement or resolution.rs. Where it fits The Accelerator is part of the Revolutionary Workplace® HPO Labs System and High Performance Teams experience. It extends Life Masters’ work on psychological safety, trust, collaboration and communication to the top of the organisation, where leadership teams are divided and need a structured way to work through the issues. Teams can move from the Accelerator into deeper work, including the High Performance Team Sprint, Execution Accelerator, Culture Reset or Executive Strategy Facilitation. Frequently asked questions What is leadership alignment? A leadership team is aligned when its members share priorities, decide and communicate consistently, and support decisions once made. How do you fix a divided executive team? By measuring where the team is out of step, then working through those gaps together in facilitated sessions, as the Accelerator does. How much does leadership alignment cost in South Africa? Entry-level interventions with Life Masters start from R35,000, with investment depending on the format, participants and depth of process. How long does an exco retreat take? Engagements range from a two-day retreat to multi-month projects. Start now Business Leadership Keynote talks and board or exco interview meetings are available immediately, ahead of programme bookings in January 2027. The interview meeting is the first step: a focused conversation to understand the team’s challenges and recommend the right format. Book a talk or interview meeting: revwork.lifemasters.co.za | Email Contact | +27 83 447 6300 Key facts Programme: Revolutionary Workplace Leadership Alignment Accelerator and diagnostics Entry level intervention investment starts from R35,000 Bookings begin January 2027, offered in Gauteng, South Africa For management, executive and board teams Founder: Tony Dovale. Website: lifemasters.co.za Questions about this announcement What is the Life Masters Leadership Alignment Accelerator? It is a new programme and diagnostic process from Life Masters for repairing and aligning fractured executive and business teams. It forms part of the Revolutionary Workplace HPO Labs System and High Performance Teams experience. How much does the Leadership Alignment Accelerator cost? Entry-level intervention investment starts from R35,000. The final scope depends on the client's structures, locations, participant numbers, and the depth of process facilitation required. When and where can teams book it? The launch begins now with talks and board or Exco interview meetings, with bookings starting in January 2027 in Gauteng, South Africa.
The post Important work from our team in Science Magazine today, showing how our diagnostic orchestrator can reason through complex medical cases, achieving greater diagnostic accuracy while reducing testing costs. appeared first on Source.
BOSTON, MA and RAPPERSWIL-JONA, SWITZERLAND - October 22, 2026 - Neovii Pharmaceuticals AG, a Swiss-headquartered, commercial-stage biopharmaceutical company with more than four decades of experience in antibody-based immunotherapies, today announced that it is advancing its Type 1 Diabetes (T1D) clinical program through a company-sponsored pivotal Phase 2 study in the United States and European Union. The international expansion builds on the ongoing investigator-initiated European GIRO (Grafalon in early onset) T1D study and is supported by U.S. Food and Drug Administration (FDA) Fast Track designation for anti-T-lymphocyte globulin (ATLG) for the prevention of declining C-peptide production in patients with recent-onset T1D. Patients have already been treated in GIRO, and clinical data are being generated. The expected 12-month efficacy and safety interim analysis will provide an important near-term milestone and inform the pivotal study program. This next stage marks an important expansion beyond transplantation and reflects Neovii’s strategy to apply its expertise in immune modulation to autoimmune and immune-mediated diseases with strong biological rationale and significant unmet medical need. In connection with this expansion, Neovii has appointed Salvatore “Salvo” Alesci, M.D., Ph.D., as Chief Medical Officer, effective October 15, 2026. Dr. Alesci will lead the company’s medical and clinical development activities, including translational medicine and regulatory strategy. He will oversee the Type 1 Diabetes program and help shape the company’s broader clinical development strategy, including the evaluation of future development opportunities. Scientific Rationale for ATLG in Type 1 Diabetes Type 1 Diabetes is a chronic autoimmune disease characterized by T-cell-mediated destruction of insulin-producing pancreatic beta cells. Many patients retain residual beta-cell function following diagnosis, and preserving this endogenous function remains an important therapeutic objective. ATLG is a polyclonal anti-T-lymphocyte globulin with preferential activity against activated T cells and broader effects across T-cell populations and immune pathways involved in autoimmune responses. Published clinical proof of concept in recent-onset Type 1 Diabetes was reported by Saudek et al. in a placebo-controlled study of ATLG. Together with other clinical evidence that modulation of pathogenic T-cell responses can preserve residual beta-cell function, these findings provide a clinical and mechanistic rationale for evaluating ATLG in the ongoing GIRO T1D study and company-sponsored pivotal Phase 2 study. ATLG has been used in transplantation medicine for more than four decades. Building on this extensive manufacturing, preclinical, and clinical experience, Neovii is now evaluating its potential role in autoimmune disease. The investigator-initiated European GIRO T1D study and the company-sponsored pivotal Phase 2 study in the United States and the European Union are complementary components of the ATLG clinical development program. Neovii is using emerging efficacy and safety data from GIRO to inform the pivotal study and support ongoing discussions with the FDA, European regulatory authorities, and other health authorities on a potential registration pathway. Executive Commentary Frederic Prince, Ph.D., Chief Executive Officer of Neovii Pharmaceuticals AG, commented: “Despite major advances in glucose monitoring and insulin delivery, Type 1 Diabetes continues to impose a substantial burden on patients. ATLG’s well-characterized activity against activated T cells, clinical proof of concept in recent-onset disease, and extensive clinical experience provide a strong foundation for its further evaluation. Building on the investigator-initiated GIRO T1D study, we are advancing a company-sponsored pivotal Phase 2 study to assess whether ATLG can preserve endogenous beta-cell function and reduce treatment burden. "As we take this important step in expanding Neovii’s clinical development activities, I am also delighted to welcome Salvo to Neovii as our Chief Medical Officer. His expertise in endocrinology, translational medicine, and clinical development will be highly valuable as we advance our Type 1 Diabetes program and evaluate future opportunities in immune-mediated diseases.” Salvatore Alesci, M.D., Ph.D., Chief Medical Officer of Neovii Pharmaceuticals AG, said: “I am excited to join Neovii at this important stage in the company’s evolution and help drive its expansion into Type 1 Diabetes and other immune-mediated diseases. Despite significant advances in disease management, preservation of endogenous beta-cell function remains an important therapeutic objective in Type 1 Diabetes. ATLG provides an opportunity to rigorously evaluate a differentiated immunomodulatory approach in a randomized clinical setting. I look forward to working with the Neovii team, investigators, patients, advocacy groups, and regulatory authorities to execute a scientifically rigorous Type 1 Diabetes development program and shape the company’s broader clinical strategy in immune-mediated diseases.” About Salvatore Alesci, M.D., Ph.D. Dr. Alesci is a physician-scientist and biopharmaceutical executive with combined expertise in endocrinology and immunology and more than 25 years of experience spanning translational medicine, clinical development, regulatory strategy and scientific and patient affairs. Throughout his career, he has held senior leadership roles in biotechnology and pharmaceutical organizations, leading multidisciplinary global programs from early research through late-stage clinical development. About Neovii Pharmaceuticals AG Neovii Pharmaceuticals AG is a Swiss-headquartered, fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based therapy for immune-mediated diseases. The company markets Grafalon® (ATLG, formerly named as ATG-F), an anti-human T-lymphocyte immunoglobulin approved in multiple countries for transplantation-related indications; approved uses vary by country. Grafalon is manufactured at Neovii’s dedicated biotechnology manufacturing facility in the Munich area and is commercialized in more than 50 countries. Building on decades of expertise in immune modulation, Neovii is expanding its research and development activities into selected autoimmune and immune-mediated diseases with significant unmet medical need. ATLG is investigational in Type 1 Diabetes and has not been approved for this use. Nothing in this release should be interpreted as promoting ATLG for an unapproved indication. Forward-Looking Statement This press release contains forward-looking statements regarding Neovii’s planned clinical development activities, regulatory interactions, clinical-study design and execution, business strategy, and potential future registration pathways. These statements are based on current beliefs, expectations, and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Clinical development outcomes, regulatory decisions, trial initiation and enrollment, safety and efficacy findings, development timelines, manufacturing readiness, and business objectives are subject to factors beyond Neovii’s control. Fast Track designation does not guarantee that ATLG will qualify for Accelerated Approval or Priority Review, that regulatory review will be completed within any particular timeframe, or that ATLG will receive marketing approval for Type 1 Diabetes. Neovii undertakes no obligation to update these forward-looking statements except as required by applicable law. Reference: Saudek, F., et al. The Review of Diabetic Studies, Vol. 1, No. 2, 2004. Media contact Neovii Pharmaceuticals AG, info@neovii.com, www.neovii.com
FORT MILL, S.C, Oct. 22, 2026 -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access.
MINNEAPOLIS, Oct. 22, 2026 -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.
Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows. By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently. LOS ANGELES, CA - October 22, 2026 - Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their two-dimensional images can make certain anatomical details more difficult to distinguish when structures overlap. In some healthcare settings, rising imaging volumes and radiologist workforce constraints can also place pressure on diagnostic services. These challenges underscore the importance of developing imaging technologies that can complement existing diagnostic approaches while integrating into established clinical environments and workflows. Nano-X Imaging (NASDAQ: NNOX) is approaching that problem from a different direction. Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmap CHARLOTTESVILLE, Va., Oct. 22, 2026 -- RIVANNA®, developer of AI-enabled clinical...
Integration brings Azimuth’s ADAS calibration identification and labor time capabilities into CCC ONE®, helping collision repairers streamline repair planning and estimating Integration brings Azimuth’s ADAS calibration identification and labor time capabilities into CCC ONE®, helping collision repairers streamline repair planning and estimating
CLICHY, France, October 22, 2026--CorWave SA, a clinical-stage medical technology company pioneering innovative cardiac assist devices, announces the completion of enrollment in its feasibility study of the CorWave Left Ventricular Assist System (LVAS). The company also presented the first clinical da